Brief Summary
This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advancedat a late stage, far along or metastatic solid tumors.
Intervention / Treatment
- Drug: BGB-A3055
- Drug: Tislelizumab
Inclusion Criteria
- Age≥18 years on the day of signing the informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. form (ICF) (or the legal age of consent in the jurisdiction in which the study is taking place, whichever is older).
- All participants are also required to demonstrate an ECOG Performance Status score of≤1 and have adequate organ function.
- Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8.
- >=1 Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Participants should be able to provide the archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (as block or unstained slides) or fresh biopsyremoval of a section of tissue to analyse for cancer cells if there is no archival tissuea group of cells that work together to perform a function at baseline. For selected cohorts, participants should be willing to provide post-treatment fresh biopsy at specified timepoints.